Treats schizophrenia. ANDA 90308, held by Barr Labs Inc. Clozapine.
As of Nov 15, 2026, ANDA 90308 (Clozapine), held by Barr Labs Inc, was first approved by FDA on Apr 9, 2018, with 10 approved supplements and 0 published complete response letters.
Clozapine orally disintegrating tablets (Clozapine ODT) is an atypical antipsychotic indicated for: Treatment of severely ill patients with schizophrenia who fail to respond adequately to standard antipsychotic treatment. Because of the risks of severe neutropenia and of seizure associated with its use, Clozapine ODT should be used only in patients who have failed to respond adequately to standard antipsychotic treatment Reducing the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder who are judged to be at chronic risk for re-experiencing suicidal behavior 1.
| Apr 9, 2018 | Original application | Approved | |
| Nov 25, 2015 | Original application | Approved |
| Clozapine25MG · tablet, orally disintegrating;oral | Clozapine | Rx |
| Clozapine100MG · tablet, orally disintegrating;oral | Clozapine | Rx |
| Clozapine12.5MG · tablet, orally disintegrating;oral | Clozapine | Rx |
| Clozapine150MG · tablet, orally disintegrating;oral | Clozapine | Rx |
| Clozapine200MG · tablet, orally disintegrating;oral | Clozapine | Rx |
| Jun 13, 2025 | Supplement 14REMS | Approved | None posted |
| Jun 13, 2025 | Supplement 15Labeling · Standard review | Approved | None posted |
| Jan 22, 2025 | Supplement 13Labeling · Standard review | Approved | None posted |
| Apr 26, 2023 | Supplement 12Labeling · Standard review | Approved | None posted |
| Nov 10, 2021 | Supplement 11REMS | Approved | None posted |
| Jul 29, 2021 | Supplement 9REMS | Approved | None posted |
| Apr 16, 2021 | Supplement 6Labeling · Standard review | Approved | None posted |
| Apr 9, 2021 | Supplement 1Labeling · Standard review | Approved | None posted |
| Feb 18, 2021 | Supplement 8REMS | Approved | None posted |
| Jan 16, 2019 | Supplement 3REMS | Approved | None posted |
| Apr 9, 2018 | Original application | Approved | |
| Nov 25, 2015 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters